Medicare GLP-1 Coverage Drives 700K New Senior Users, Lilly Claims 70% Share
Eli Lilly's CEO says 700,000 seniors began GLP-1 therapy after Medicare coverage launched in July, with roughly 70% choosing Lilly products.
Eli Lilly's chief executive disclosed that approximately 700,000 Medicare-eligible seniors have initiated GLP-1 treatment since the federal program expanded coverage for the drug class in July, with the company capturing about 70 percent of that new patient volume.
The figures represent the most concrete public accounting yet of how significantly the Medicare policy shift has broadened access to glucagon-like peptide-1 medications, a class of drugs that has reshaped treatment approaches for obesity and related metabolic conditions. Prior to the coverage expansion, cost remained a substantial barrier for many older Americans on fixed incomes.
Read more Midterm Voters Alarmed by National Debt, but Big Fixes Unlikely →
Lilly's dominant share of the newly covered patient population underscores the competitive advantage the Indianapolis-based drugmaker holds in the GLP-1 market, where its branded therapies compete alongside rival products from companies including Novo Nordisk. The CEO's comments signal that the Medicare expansion is translating into measurable commercial gains for Lilly, not merely broadening the overall market.
The data also carries policy relevance at a time when federal officials and lawmakers continue to scrutinize the long-term budgetary implications of covering high-cost obesity and diabetes drugs under Medicare. How quickly the senior patient population grows — and which manufacturers capture that growth — will factor into ongoing negotiations over drug pricing and formulary design.
Continue reading at Business News.
